| Private Placement / Financing Transactions
Nuvaira: The company raised $15.1 million of venture funding from undisclosed investors on November 30, 2023. The company is a developer of a medical device designed to improve outcomes for patients suffering from obstructive lung diseases.
Innovo Therapeutics: The company raised nearly CNY 100 million of Series Pre-A venture funding in a deal led by Huajin Investment on December 1, 2023. Hainan Longmen Fund, Zhongjince Investment, Ming Bioventures and Unifortune Investment also participated in the round. The company is a developer of novel protein degrader drugs intended for cancer treatment.
Centrexion Therapeutics: The company raised $12.6 million of venture funding in the form of convertible debt from Plutus Investment Group and other undisclosed investors on November 27, 2023. The company is an operator of a clinical-stage biopharmaceutical company intended to address the unmet medical need for the treatment of chronic pain.
Biolexis Therapeutics: The company raised $10 million of Series A venture funding in a deal led by Clarke Capital Partners on November 29, 2023, putting the company’s pre-money valuation at $21.5 million. The company is a developer of an AI-enabled discovery platform designed to develop potent and selective small molecule therapeutics.
mk2 Biotechnologies: The company is in the process of raising $9 million of Series A venture funding on November 28, 2023. The company is a developer of a peptide and protein purification synthesis technology designed to improve the process of conventional chemical synthesis.
Eikonoklastes Therapeutics: The company raised $6.6 million of venture funding in the form of convertible debt from undisclosed investors on November 27, 2023. The company is a developer of therapies designed to assist in the treatment of solid tumors and other pathologic conditions.
Encellin: The company raised $5.9 million of Series A venture funding from Evolution VC Partners, SVLC and Khosla Ventures on November 28, 2023, putting the company’s pre-money valuation at $35 million. Formic Ventures, Ascendant Venture, California Innovation Fund, Pier 70 Ventures, Y Combinator and Sand Hill Angels also participated in the round. The company is an operator of a biotechnology business intended to develop a novel thin-film cell encapsulation device for cell-based therapeutics.
Kernel: The company raised $5.3 million of venture funding from undisclosed investors on December 1, 2023. The company is a developer of brain recording technologies designed to augment human intelligence and treat neurodegenerative diseases.
Oncovita: The company raised EUR 3.5 million of venture funding from undisclosed investors on November 29, 2023. The company is an operator of a biotech firm intended to develop cancer treatment therapies.
3Helix: The company raised $3.8 million of venture funding from BASF and other undisclosed investors on November 29, 2023. The company is a developer of a novel collagen-targeting technology designed to help in the diagnosis of diseases with high collagen remodeling activities.
AmacaThera: The company raised CAD 4 million of Series A venture funding in a deal led by Paul Austin on November 28, 2023. BDC Capital, Lumira Ventures, MaRS Investment Accelerator Fund, and Inveready Asset Management also participated in the round. The company is a developer of an injectable hydrogel technology designed to localize and sustain drug delivery and improve patient outcomes across multiple therapeutic areas.
QSimulate: The company raised $2.5 million of venture funding in a deal led by 2xN on November 27, 2023. Kyoto University Innovation Capital and UTokyo Innovation Platform also participated in the round. The company is a developer of tools designed to help in quantum molecular simulations.
|
